Hori T
Cancers (Basel). 2024; 16(17).
PMID: 39272967
PMC: 11394586.
DOI: 10.3390/cancers16173109.
Sun Y, Wu Y, Pang G, Huang J, Sheng M, Xie J
Leukemia. 2024; 38(10):2102-2114.
PMID: 39179670
DOI: 10.1038/s41375-024-02383-8.
Lints R, Walker C, Delfi O, Prouse M, PohLui De Silva M, Bohlander S
Biol Open. 2024; 13(9).
PMID: 39177514
PMC: 11381922.
DOI: 10.1242/bio.060523.
Joshi P, Keyvani Chahi A, Liu L, Moreira S, Vujovic A, Hope K
Hemasphere. 2024; 8(8):e116.
PMID: 39175825
PMC: 11339706.
DOI: 10.1002/hem3.116.
Kreissig S, Windisch R, Wichmann C
Cells. 2024; 13(1).
PMID: 38201282
PMC: 10777941.
DOI: 10.3390/cells13010078.
Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo.
Neldeborg S, Soerensen J, Moller C, Bill M, Gao Z, Bak R
Leukemia. 2023; 37(9):1792-1801.
PMID: 37464068
PMC: 10457201.
DOI: 10.1038/s41375-023-01950-9.
HIF1α-mediated transactivation of WTAP promotes AML cell proliferation via mA-dependent stabilization of KDM4B mRNA.
Shao Y, Li Y, Li M, Wang L, Zhou H, Liu D
Leukemia. 2023; 37(6):1254-1267.
PMID: 37087529
DOI: 10.1038/s41375-023-01904-1.
, a novel RUNX1 target gene, is down-regulated by RUNX1-ETO.
Matsumoto A, Yoshida T, Shima T, Yamasaki K, Tadagaki K, Kondo N
BBA Adv. 2023; 2:100047.
PMID: 37082605
PMC: 10074976.
DOI: 10.1016/j.bbadva.2022.100047.
PU.1-c-Jun interaction is crucial for PU.1 function in myeloid development.
Zhao X, Bartholdy B, Yamamoto Y, Evans E, Alberich-Jorda M, Staber P
Commun Biol. 2022; 5(1):961.
PMID: 36104445
PMC: 9474506.
DOI: 10.1038/s42003-022-03888-7.
Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective.
Hayashi Y, Harada Y, Harada H
Leukemia. 2022; 36(5):1203-1214.
PMID: 35354921
DOI: 10.1038/s41375-022-01548-7.
brca2-mutant zebrafish exhibit context- and tissue-dependent alterations in cell phenotypes and response to injury.
Kouprianov V, Selmek A, Ferguson J, Mo X, Shive H
Sci Rep. 2022; 12(1):883.
PMID: 35042909
PMC: 8766490.
DOI: 10.1038/s41598-022-04878-9.
Modelling t(8;21) acute myeloid leukaemia - What have we learned?.
Chin P, Bonifer C
MedComm (2020). 2021; 1(3):260-269.
PMID: 34766123
PMC: 8491201.
DOI: 10.1002/mco2.30.
The telomere complex and the origin of the cancer stem cell.
Torres-Montaner A
Biomark Res. 2021; 9(1):81.
PMID: 34736527
PMC: 8567692.
DOI: 10.1186/s40364-021-00339-z.
AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms.
Rejeski K, Duque-Afonso J, Lubbert M
Oncogene. 2021; 40(38):5665-5676.
PMID: 34331016
PMC: 8460439.
DOI: 10.1038/s41388-021-01952-w.
Cytogenetics of Pediatric Acute Myeloid Leukemia: A Review of the Current Knowledge.
Quessada J, Cuccuini W, Saultier P, Loosveld M, Harrison C, Lafage-Pochitaloff M
Genes (Basel). 2021; 12(6).
PMID: 34204358
PMC: 8233729.
DOI: 10.3390/genes12060924.
Fusion Genes and RNAs in Cancer Development.
Taniue K, Akimitsu N
Noncoding RNA. 2021; 7(1).
PMID: 33557176
PMC: 7931065.
DOI: 10.3390/ncrna7010010.
MicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3'UTR.
Johnson D, Davis A, Zhou J, Ball E, Zhang D
Exp Hematol Oncol. 2021; 10(1):8.
PMID: 33531067
PMC: 7856722.
DOI: 10.1186/s40164-021-00204-7.
Gamma-radiated immunosuppressed tumor xenograft mice can be a new ideal model in cancer research.
Khodayari H, Khodayari S, Khalighfard S, Tahmasebifar A, Tajaldini M, Poorkhani A
Sci Rep. 2021; 11(1):256.
PMID: 33420261
PMC: 7794493.
DOI: 10.1038/s41598-020-80428-5.
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.
Jahn N, Terzer T, Strang E, Dolnik A, Cocciardi S, Panina E
Blood Adv. 2020; 4(24):6342-6352.
PMID: 33351131
PMC: 7757000.
DOI: 10.1182/bloodadvances.2020002673.
A Novel Platform to Test In Vivo Single Gene Dependencies in t(8,21) and t(15,17) AML Confirms Zeb2 as Leukemia Target.
De Conti G, Gruszka A, Valli D, Cammarata A, Righi M, Mazza M
Cancers (Basel). 2020; 12(12).
PMID: 33327558
PMC: 7765008.
DOI: 10.3390/cancers12123768.